Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Paclitaxel 18Carboplatin 14Topotecan 8liposomal doxorubicin 6Cyclophosphamide 5Cisplatin 5Gemcitabine 4Docetaxel 4oregovomab 3Immunoenzyme Techniques 3Etoposide 3Capecitabine 3pembrolizumab 2fludarabine phosphate 2aldesleukin 2Taxes 2Surgical Procedures, Operative 2Stem Cell Transplantation 2STA 9090 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Nivolumab 2Microarray Analysis 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Fulvestrant 2Fluorodeoxyglucose F18 2Flow Cytometry 2Filgrastim 2Cytoreduction Surgical Procedures 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Ovarian Epithelial × veliparib × Clear all
NCT01233505 2014-04-02

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Terminated
16 enrolled
BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡